Intravenous infusion of N-acetylcysteine + Intravenous infusion of Fomepizole (4-MP)
Phase 2Terminated 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Acetaminophen
Conditions
Acetaminophen, Drug Overdose, Acetaminophen Overdose, Acetaminophen Poisoning, Drug-induced Liver Injury, Liver Failure, Liver Toxicity
Trial Timeline
Sep 12, 2022 → Nov 8, 2025
NCT ID
NCT05517668About Intravenous infusion of N-acetylcysteine + Intravenous infusion of Fomepizole (4-MP)
Intravenous infusion of N-acetylcysteine + Intravenous infusion of Fomepizole (4-MP) is a phase 2 stage product being developed by Johnson & Johnson for Acetaminophen. The current trial status is terminated. This product is registered under clinical trial identifier NCT05517668. Target conditions include Acetaminophen, Drug Overdose, Acetaminophen Overdose.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05517668 | Phase 2 | Terminated |
Competing Products
1 competing product in Acetaminophen
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Acetaminophen | Johnson & Johnson | Approved | 85 |